Ibogaine is classified as a controlled and prohibited substance in Brazil under the regulatory authority of ANVISA (Agência Nacional de Vigilância Sanitária), making its use, possession, and distribution illegal outside of any authorized research contexts. Last verified: April 2026.

Current Legal Status

In Brazil, controlled substances are regulated by ANVISA, the federal health surveillance agency responsible for publishing and maintaining lists of prohibited, controlled, and regulated psychoactive compounds. Ibogaine — the primary active alkaloid found in the Tabernanthe iboga plant — appears on ANVISA's controlled and prohibited substances lists, placing it in a category that restricts its manufacture, sale, import, export, possession, and therapeutic use without specific governmental authorization.

ANVISA organizes controlled substances into several regulatory lists (referred to internally as "listas" within its published normative resolutions). Substances in the prohibited category face the strictest controls, with no licensed commercial pathway for clinical or personal use currently established for ibogaine in Brazil. Because ANVISA periodically updates these lists through Resoluções da Diretoria Colegiada (RDC), the specific list designation and associated controls for ibogaine should be verified directly against ANVISA's current published documentation at anvisa.gov.br.

Brazil's broader drug control framework is also shaped by Lei nº 11.343/2006 (the National Drug Policy Law), which establishes criminal and administrative penalties for unauthorized handling of controlled substances. Ibogaine's ANVISA classification means it falls under the scope of this law, potentially exposing individuals involved in its unauthorized use or distribution to criminal liability.

Important: ANVISA's controlled substance lists are subject to revision. The classification described here reflects ibogaine's status as understood in April 2026. Always consult the official ANVISA portal for the most current scheduling information before making any decisions.

There are no known religious carve-outs or indigenous use exemptions specifically protecting ibogaine in Brazil. This contrasts with other psychoactive plants such as ayahuasca, which received a specific regulatory carve-out from ANVISA in 2010 recognizing its traditional and religious use. No equivalent framework currently exists for iboga or ibogaine.

Treatment Centers

Because ibogaine is classified as a prohibited controlled substance by ANVISA, there are no openly licensed ibogaine treatment clinics operating legally within Brazil. Any facility claiming to offer ibogaine-assisted therapy within Brazilian territory would be doing so outside of the legal framework established by ANVISA and Lei nº 11.343/2006.

Brazilians seeking ibogaine treatment most commonly travel to neighboring countries where the substance is either unscheduled or where regulated treatment centers operate legally — most notably Mexico and Portugal, both of which have established ibogaine clinic ecosystems.

For a comprehensive directory of vetted ibogaine treatment centers operating in legal jurisdictions, visit our full clinic directory.

How People Access Ibogaine in Brazil

Despite its controlled status, ibogaine does circulate in Brazil, and people access it through several informal channels. This section describes those pathways factually — it does not constitute a recommendation to pursue any of them.

  • Medical tourism: The most common route for Brazilians seeking ibogaine treatment is traveling abroad to countries with legal or tolerated treatment centers, particularly Mexico, where numerous clinics operate openly near the US border and in resort areas, and Portugal, where ibogaine is unscheduled.
  • Underground or informal settings: Some individuals access ibogaine through informal networks within Brazil. These settings operate entirely outside any regulatory oversight and carry significant safety risks, including lack of medical screening, no emergency protocols, and potential legal exposure for all parties involved.
  • Research participation: A small number of clinical researchers in Brazil have explored psychedelic-assisted therapies, but as of April 2026, no publicly known authorized research program specifically involving ibogaine has been widely reported. Anyone interested in this pathway would need to engage directly with Brazilian academic or medical institutions for information on any authorized protocols.
  • Iboga plant material: The Tabernanthe iboga plant itself may exist in a legal gray area depending on its specific ANVISA classification. However, because ibogaine is the targeted controlled alkaloid, possession of plant material with intent to extract or consume ibogaine would likely be treated as possession of a controlled substance.

Safety notice: Ibogaine carries serious cardiovascular risks, including potentially fatal cardiac arrhythmias. Accessing it outside of medically supervised settings significantly increases these risks. If you are considering ibogaine therapy, thorough medical screening and cardiac evaluation are essential regardless of where treatment is sought.

Recent Legal Developments

Brazil has experienced a broader cultural and scientific conversation about psychedelic therapies over the past several years, mirroring global trends. However, as of April 2026, no specific legislative or regulatory movement to reschedule, decriminalize, or create a therapeutic pathway for ibogaine in Brazil has advanced to a formal policy stage.

Key recent context includes:

  • Global ibogaine momentum: Internationally, ibogaine has attracted significant clinical attention, particularly following high-profile research published by Stanford University scientists examining its potential for treating traumatic brain injury and opioid use disorder. This global momentum has raised awareness in Brazilian medical and policy communities, though it has not yet translated into domestic regulatory reform.
  • Psychedelic research expansion in Brazil: Brazilian researchers and institutions have shown increasing interest in psychedelic-assisted therapies broadly, with ayahuasca research being the most developed area. This general scientific openness may eventually create favorable conditions for ibogaine research discussions, but no formal proposal targeting ibogaine has been publicly announced by ANVISA or Brazilian health ministries in this period.
  • ANVISA scheduling reviews: ANVISA conducts periodic reviews of its controlled substance lists. Interested parties — including researchers and healthcare providers — can formally petition ANVISA to review the scheduling status of specific substances. No successful petition specifically targeting ibogaine's rescheduling has been publicly documented as of April 2026.

Risks of Seeking Treatment in Brazil

For individuals considering ibogaine therapy who are based in Brazil, understanding the specific risk landscape is essential:

  • Legal risk: Participating in ibogaine use within Brazil, even as a patient, carries potential legal exposure under Lei nº 11.343/2006. While enforcement priorities vary and personal drug use has historically been treated less harshly than trafficking in Brazil, there is no guaranteed legal protection for ibogaine consumers.
  • Absence of quality control: Without any licensed supply chain, ibogaine obtained through informal Brazilian networks has no guarantee of purity, dosage accuracy, or freedom from adulterants. Misdosing ibogaine — a substance with a notoriously narrow therapeutic window — is life-threatening.
  • No medical oversight standards: Informal providers operating underground in Brazil are not subject to ANVISA medical standards, meaning there is no requirement for cardiac screening (EKG/ECG), contraindication screening, or emergency medical protocols. These omissions are among the primary contributors to ibogaine-related fatalities globally.
  • No legal recourse: If harm occurs in an unlicensed setting, patients have no legal recourse through standard medical regulatory channels, and providers have strong incentives to avoid accountability.
  • Medical tourism considerations: For Brazilians traveling abroad for treatment, risks shift toward the quality and legitimacy of the chosen foreign clinic. Not all clinics in Mexico or other popular destinations operate to the same standard of care. Thorough vetting of any facility — including verifying medical staff credentials, emergency protocols, and client screening processes — is critical.

Frequently Asked Questions

No. Ibogaine is classified as a controlled and prohibited substance by ANVISA, Brazil's federal health surveillance authority. Its use, possession, sale, and distribution are prohibited outside of any specifically authorized research context. There is no licensed therapeutic or personal use pathway currently established in Brazil. Verify the current classification at anvisa.gov.br, as ANVISA's lists are subject to periodic revision.
ANVISA (Agência Nacional de Vigilância Sanitária) is Brazil's federal agency responsible for regulating food, medicines, medical devices, cosmetics, and controlled substances. It publishes and maintains normative lists — established through Resoluções da Diretoria Colegiada (RDC) — that classify psychoactive substances as prohibited, controlled, or regulated. Because ibogaine is a psychoactive alkaloid with no currently approved therapeutic application in Brazil, it falls under ANVISA's prohibited/controlled substance framework.
No. There are no known legally licensed ibogaine treatment clinics operating within Brazil. Any facility within Brazilian territory offering ibogaine-assisted sessions would be operating outside of the regulatory framework established by ANVISA and federal drug law. Brazilians who pursue ibogaine therapy typically do so by traveling to countries where it is legal or unscheduled, such as Mexico or Portugal. See our clinic directory for vetted options in legal jurisdictions.
As of April 2026, there is no formal legislative or regulatory proposal before ANVISA or the Brazilian Congress specifically targeting ibogaine rescheduling. While Brazil has a growing research culture around psychedelic-assisted therapies — particularly with ayahuasca — and while global ibogaine research momentum is increasing, no concrete policy movement toward rescheduling ibogaine in Brazil has been publicly announced. The situation could evolve; monitoring ANVISA's official communications is the most reliable way to track changes.
No. Ayahuasca received a specific carve-out from ANVISA in 2010 recognizing its traditional and religious ceremonial use, removing DMT-containing ayahuasca preparations from ANVISA's prohibited list for that specific context. This exemption is based on decades of documented cultural and religious use in Brazil and is specific to ayahuasca. Ibogaine has no equivalent carve-out, no recognized traditional use framework in Brazil, and no separate regulatory pathway. Its controlled status is independent of and unaffected by ayahuasca's legal situation.
The risks are substantial and span legal, medical, and safety dimensions. Legally, participation in ibogaine use in Brazil exposes individuals to potential criminal liability under Lei nº 11.343/2006. Medically, ibogaine poses serious cardiovascular risks — including potentially fatal cardiac arrhythmias — that require prior screening via ECG, full cardiac workup, and contraindication review. Informal providers in Brazil are not regulated by ANVISA medical standards and have no obligation to conduct this screening. There is also no quality control on informally obtained ibogaine, raising the risk of impure or incorrectly dosed product. If an adverse event occurs, no legal medical infrastructure supports patients in unlicensed settings.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.